A pilot open label study of Acetazolamide as an adjuvant to anti-psychotic treatment in patients with schizophrenia

IVERSITY OF PITTSBURGH0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Diagnosed as schizophrenia by DSM 5 criteria using Structured Clinical Interview for DSM disorders (SCID), aged between 18-50 years.
•Patients who have residual positive symptoms and are clinically stable.
•Residual positive symptoms criteria: Participants will be required to meet the following symptom criteria: 1) PANSS total score of 60 or more, and 2) a PANSS score of 4 or more on at least one positive symptom. Stability Criteria and concomitant Antipsychotic drug use (APD): Participants will be clinically stable and treated with the same APD for at least 60 days with a constant therapeutic dose for at least 30 days prior to the study. There will not be any restrictions on the type of APD with which the participant is treated, except patients administered clozapine for less than one year prior to study admission, since they require frequent blood tests.
•Without any co-morbid psychiatric illness other than nicotine and caffeine use

•Persons currently on Acetazolamide or Thiamine for any medical reasons.
•Suicidal ideation currently
•Already diagnosed medical conditions in which acetazolamide is contraindicated like hyperchloremic acidosis, hypokalemia, hyponatremia, adrenal insufficiency, impaired kidney function, hypersensitivity to acetazolamide or other sulphonamides, liver diseases as per baseline clinical examination and relevant biochemical tests.
•Persons taking any other diuretics and Aspirin.
•Pregnant and lactating women (Pregnancy test will be done prior to the recruitment)
•Persons diagnosed with intellectual disability
•Known hypersensitivity to sulphonamide derivatives

发起方

IVERSITY OF PITTSBURGH